



Dear colleagues,

On behalf of the Communication & Dissemination International Advisory Committee of the WOMAN (World Maternal Antifibrinolytic) trial, I am writing to invite you to join us as we prepare for the results of this important study.

We know of your personal interest in improving the health of mothers, especially in projects working towards saving the lives of new mothers and your commitment to the Millennium Development Goal (MDG) of reducing maternal deaths and the new Sustainable Development Goals (SDGs). WOMAN is a multi-centre randomised controlled trial to see if tranexamic acid (TXA) reduces death and hysterectomy and improves other clinically important outcomes in 20,000 women with postpartum haemorrhage (PPH). We have now successfully completed recruitment of 20,000 women from 21 countries across the globe.

The WOMAN trial has recruited from Albania, Bangladesh, Burkina Faso, Cameroon, Colombia, Cote d'Ivoire, Democratic Republic of Congo, Egypt, Ethiopia, Ghana, Jamaica, Kenya, Nepal, Nigeria, Pakistan, Papua New Guinea, Sudan, Tanzania, Uganda, United Kingdom and Zambia. We

would like to invite you to join the trial network to enable all medical professionals across the globe to gain access to the results and give women everywhere the greatest opportunity to benefit from the results.

PPH accounts for about 25% of maternal deaths. An effective treatment could save tens of thousands of lives, prevent many unnecessary hysterectomies and reduce exposure to the risks of blood transfusion. TXA is a relatively cheap, old drug with an expired patent and promising results from supporting studies. The CRASH-2 trial of TXA in bleeding trauma patients provides grounds for hope that TXA might also save lives in PPH. The current global burden of postpartum haemorrhage requires action to identify treatments and implement change.

If you would like to join, please register your interest by email (TheWomanTrial@Lshtm.ac.uk), fax or post. You will find more information on the website (www.TheWomanTrial.Lshtm.ac.uk), or you can contact the Trial Co-ordinating Centre by phone, letter or email.

We look forward to sharing this pivotal research with you. Yours sincerely,

Professor C N Purandare Professor Hamid Rushwan Associate Professor
Haleema Shakur FIGO President FIGO Chief Executive WOMAN Project
Director